Karachi: Abbott Laboratories (Pakistan) Limited has scheduled a virtual meeting of its Board of Directors for October 25, 2024, to discuss the company's financial results for the quarter ending September 30, 2024. This meeting aims to review and consider the quarterly accounts in accordance with corporate governance and financial reporting standards.

The company has officially entered a "Close Period" starting from October 18, 2024, until the date of the board meeting, October 25, 2024. During this period, all directors, the CEO, and executive management are prohibited from trading the company’s shares. This measure is in compliance with Clause 5.6.4 of PSX Regulations, ensuring transparency and fairness in handling insider information.

According to information available from the Pakistan Stock Exchange (PSX), the enforcement of a Close Period is a standard practice aimed at preventing any insider trading or conflicts of interest that might arise from the misuse of unpublished financial information. It is a critical time when companies are expected to uphold strict confidentiality regarding their financial operations until the information is officially released to the public and shareholders.

Shareholders and investors of Abbott Laboratories are advised to note the scheduled board meeting and the ongoing Close Period. The company's adherence to these regulations reflects its commitment to ethical corporate practices and maintaining shareholder trust.